Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Diagnosed in 2012 Stage IV NSCLC, malignant pleural effusion. EGFR positive, started Tarceva which kept cancer at bay for 20 mos. Negative for T790 mutation so I started Carbo and Alimta and then Alimta maintenance. After a few months on Alimta, more progression. Was able to start Opdivo (Nivolumab) off label before FDA apporoval. Did well on it together with some radiation of a tumor that was occluding the bronchus.
To date, I have been on Opdivo for 11 mos. Recent CT scan shows new progression. Looking into other options and was wondering if anyone had success trying Tarceva a second time? I have been off it for about a year now. Are there any new drugs that are being used successfully with Opdivo?
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Reply # - May 10, 2016, 11:47 AM
Hi sunshine4me,
Hi sunshine4me,
Welcome to GRACE, and congratulations on the good responses you've had to treatment. When a patient has an extended response to a first-line TKI, as you did with Tarceva, rechallenging at a later date is a viable option, even if it's not really expected to be quite as effective as it initially was. Other options include further targeted therapy, either using one of the third-generation EGFR TKIs, which may be effective even in the absence of a T790M mutation, or one of the options Dr. Pennell discusses here. It's also possible to try a different chemo regimen.
Immunotherapy combinations are just beginning to be studied, and are the subject of a recent podcast by Dr. Garon.
Good luck with your next line of therapy.
JimC
Forum moderator